|
|
|
| Influence of Somatostatin on Serum Levels of Occludin IL-8 and IL-2 and Mucosal Barrier Function of Patients with Severe Acute Pancreatitis |
| FU Xiaolin, DUAN Ying, ZHANG Yi, et al |
| Xianyang Central Hospital, Shaanxi Xianyang 712000, China |
|
|
|
|
Abstract Objective: To investigate the influence of somatostatin on the levels of occludin, interleukin-8 (IL-8) and interleukin-2 (IL-2) and mucosal barrier function of patients with severe acute pancreatitis. Methods: From October 2014 to October 2016, 98 patients with acute severe pancreatitis admitted in our hospital were selected and divided into the control group and the experimental group, with 49 cases in each group according to different treatment methods. The control group was treated with conventional western medicine, while the experimental group was treated with somatostatin on the basis of control group. Then the curative effect, bowel sounds, first defecation, abdominal pain, abdominal distension relief, 3 days and 7 days after treatment, serum levels of occludin, IL-8, IL-2, urinary lactulose/mannitol (L/M) urine, D-lactic acid, APACHE Ⅱ score and incidence of adverse reactions before and after treatment were observed and compared between the two groups. Results: After treatment, the total effective rate was higher than that of the control group, and the bowel sounds, first time defecation, abdominal pain, abdominal distension relief time of experimental group were significantly shorter than those of the control group (P<0.05). The serum occludin and IL-2 levels of experimental group were significantly higher than those before treatment (P>0.05). The above indicators of experimental group were significantly higher than those of the control group; the serum IL-8, urine L/M value, D-lactic acid, APACHE Ⅱ scores of both groups were significantly lower than those before treatment, and the above indicators of experimental group were significantly lower than those of the control group (P<0.05). The incidence rate of adverse reaction showed no differences between the two groups (P>0.05). Conclusion: Somatostatin adjuvant therapy can improve the clinical efficacy in the treatment of patients with acute severe pancreatitis, alleviate the barrier of the mucosa barrier and improve the serum occludin, IL-8 and IL-2 levels.
|
|
|
|
|
|
[1] 余珊,周贤.重症急性胰腺炎合并胃肠损害机制的研究进展[J].山东医药,2015,55(45):102~105.
[2] 叶剑飞.生长抑素、丹参联合治疗对重症急性胰腺炎患者预后及血清水平因子影响的观察[J].临床急诊杂志,2016,17(11):848~851.
[3] 王鑫,刘爱香,郑贞苍,等.生长抑素联合加贝酯对老年重症急性胰腺炎患者细胞因子及肠黏膜功能的影响[J].中国中西医结合消化杂志,2015,23(08):553~555,558.
[4] 翟宏军,张心武,孙晓力,等.重症急性胰腺炎患者血清炎性因子含量与全身靶器官损伤的关系研究[J].海南医学院学报,2017,23(14):1892~1895.
[5] 张圣道,雷若庆.重症急性胰腺炎的诊治规范与指南解读[J].中华外科杂志,2009,47(19):1441~1443.
[6] 徐兆军,别华容,田敏,等.生长抑素联合前列地尔对重症急性胰腺炎患者的疗效及对TNF-αIL-6的影响[J].河北医学,2016,22(2):266~269.
[7] 姜素伟,程子安.生长抑素联合泮托拉唑钠治疗重症急性胰腺炎的临床观察[J].中国药房,2015,13(18):2493~2495.
[8] 蔡艳萍,王萍.生长抑素联合奥美拉唑对急性胰腺炎血清炎性因子与肠道黏膜屏障功能的影响[J].河北医药,2017,39(17):2641~2643.
[9] 介卫华,李爱红.急性胰腺炎患者肠黏膜屏障功能损害相关研究[J].新乡医学院学报,2014,31(5):391~394.
[10] 龙涛,王啸,白蓉蓉.乌司他丁联合生长抑素治疗老年急性重症胰腺炎的疗效及对患者血清TNF-α、IL-6、IL-8影响的研究[J].中国现代医学杂志,2015,25(21):96~99. |
|
|
|
2018, Vol. 24 
